

## Update on Fire Incident at Biocartis Warehouse

**Mechelen, Belgium, 2 August 2021** – Biocartis Group NV (the 'Company' or 'Biocartis') (Euronext Brussels: BCART) provides an update regarding the impact on production and inventory following a fire that broke out at one of the Company's warehouse facilities in Mechelen, Belgium, during the night of 30 July 2021.

### Production Continuity

The fire caused considerable damage to the warehouse facility. In the adjacent production facility, the manufacturing equipment of the high-throughput 'ML2' cartridge production line was not damaged but due to structural damages to the building, and the inspections and repairs needed, production at the 'ML2' line will be temporarily suspended.

Production will be transferred from the impacted 'ML2' production line to the 'ML1' production line which is located in another building at the Mechelen site and that was not affected by the fire. Steps have been taken to redirect additional personnel and resources to the 'ML1' line and increase its output, but the Company will be running at considerably lower manufacturing capacity until production on ML2 can be resumed.

### Inventory Update

A part of the stock of finished products and reagents used as raw materials in Idylla™ cartridge manufacturing was lost in the fire. However, as the Company stores inventory across different warehouses, the stock of instruments and consoles was not impacted and about half of the Company's stock of finished products is still available to meet short term demand across the majority of the product portfolio. Also, inventory of plastic parts was unaffected.

Raw material is available to continue cartridge manufacturing until late August and steps will be taken the coming days to replenish critical reagent materials from different suppliers in order to minimize production delays.

We will be working closely with our customers and partners to minimize the impact of these disruptions in production and to secure serving most urgent needs.

Further updates will be made as appropriate.

--- END ---

### Contact information:

Jean-Marc Roelandt  
Chief Financial Officer Biocartis  
e-mail [jroelandt@biocartis.com](mailto:jroelandt@biocartis.com)  
mobile +32 477 95 25 08

[@Biocartis](https://twitter.com/Biocartis) [www.linkedin.com/Biocartis](https://www.linkedin.com/Biocartis)

### About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for SARS-CoV-2 and sepsis. More information: [www.biocartis.com](http://www.biocartis.com). Follow us on [@Biocartis\\_](https://twitter.com/Biocartis).

Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of

securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

**Forward-looking statements**

*Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.*